Shots:
The US FDA has accepted the resubmitted BLA for Xbrane's Lucamzi, a biosimilar to Lucentis, & assigned a BsUFA action date of Oct 29, 2026
The resubmission, completed in Apr 2026, addressed issues identified in the CRL received from the FDA in Oct 2025
The product is already approved & marketed in EU as…
